What is the current Price Target for the Syros Pharmaceuticals, Inc. stock?

The average Syros Pharmaceuticals, Inc. target price is $20.00. This is 82,544.60% higher than the current stock price. 1 Analyst has issued a Syros Pharmaceuticals, Inc. price target 2026.

How high will the Syros Pharmaceuticals, Inc. stock rise?

No reliable answer can be given as to how high the Syros Pharmaceuticals, Inc. stock will rise. The performance of stocks, including the Syros Pharmaceuticals, Inc. stock, depends on a variety of factors, such as the general economic situation, the company's business results, investor expectations and global events.

What's going on with the Syros Pharmaceuticals, Inc. stock today?

The performance of Syros Pharmaceuticals, Inc. stock on any given day can be influenced by various factors, such as market conditions, industry trends, company news and global events.

Why did the Syros Pharmaceuticals, Inc. stock fall?

The decline in Syros Pharmaceuticals, Inc. stock may be due to a variety of factors, such as market conditions, industry trends, company news, macroeconomic events or changes in investor expectations. It is important to note that stock markets are inherently volatile and the performance of an individual stock on any given day is not necessarily indicative of its long-term performance.

What is a price target?

A price target is an estimate by an analyst or investment bank of where a company's stock price could be in a certain period of time, usually 12 months.

Syros Pharmaceuticals, Inc. Forecast, price target & analysts

$0.02

27.69% today

Nasdaq, Apr 04, 06:29 pm CET

ISIN

US87184Q1076

Symbol

SYRS

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Biotechnology

Overview Dividends Analysts Charts News Strategies

Syros Pharmaceuticals, Inc. Target price 2025 - Analyst rating & recommendation

Syros Pharmaceuticals, Inc. Classifications & Recommendation:

Buy

50%

Hold

50%

Syros Pharmaceuticals, Inc. Price Target

Target Price	$20.00
Price	$0.02
Potential	82,544.60% register free of charge
Number of Estimates	1

	1 Analyst has issued a Syros Pharmaceuticals, Inc. price target 2026. The average Syros Pharmaceuticals, Inc. target price is $20.00. This is 82,544.60% register free of charge higher than the current stock price.
	A rating was issued by 2 analysts: 1 Analysts recommend Syros Pharmaceuticals, Inc. to buy, 1 to hold and 0 to sell.
	Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
	Analyst Estimates: Analysts believe that the Syros Pharmaceuticals, Inc. stock has an average upside potential 2026 of 82,544.60% register free of charge . Most analysts recommend the Syros Pharmaceuticals, Inc. stock at Buy or hold.

Earnings per share, P/E ratio and EV/sales Estimates 2024, 2025 to 2028

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually

	Dec '23	2024 Estimates
Earnings Per Share $	-5.81	-1.50
	22.43%	74.18%
P/E		negative

1 Analysts have issued a Syros Pharmaceuticals, Inc. forecast for earnings per share. The average Syros Pharmaceuticals, Inc. EPS is

Unlock

. This is

Unlock

than earnings per share in the financial year 2023. The highest EPS forecast is

Unlock

, the lowest is

Unlock

This results in the following potential growth metrics and future valuations:

2023	$-5.81	22.43%
2024	$-1.50 74.18% Unlock
2025	$-0.95 36.67% Unlock
2026	$-0.60 36.84% Unlock
2027	$-0.65 8.33% Unlock
2028	$-0.65 0.00% Unlock

Current	-0.01	98.92%
2024	-0.02 100.00% Unlock
2025	-0.03 50.00% Unlock
2026	-0.04 33.33% Unlock
2027	-0.04 0.00% Unlock
2028	-0.04 0.00% Unlock

Syros Pharmaceuticals, Inc....

Current Syros Pharmaceuticals, Inc. Upgrades & Downgrades

Create a Premium account to unlock Upgrades/Downgrades. Learn more

Analyst	Rating	Action	Date
Brookline Capital	Locked ➜ Locked	Locked	Nov 13 2024
HC Wainwright & Co.	Locked ➜ Locked	Locked	Nov 13 2024
JMP Securities	Locked ➜ Locked	Locked	Nov 13 2024
TD Cowen	Locked ➜ Locked	Locked	Nov 13 2024
HC Wainwright & Co.	Locked ➜ Locked	Locked	Nov 01 2024

Analyst Rating	Date
Locked Brookline Capital: Locked ➜ Locked	Nov 13 2024
Locked HC Wainwright & Co.: Locked ➜ Locked	Nov 13 2024
Locked JMP Securities: Locked ➜ Locked	Nov 13 2024
Locked TD Cowen: Locked ➜ Locked	Nov 13 2024
Locked HC Wainwright & Co.: Locked ➜ Locked	Nov 01 2024

Discover more stocks with a high price target

Novo Nordisk 83.92%

Coinbase Global, Inc. 83.53%

BioNTech SE - ADR 50.09%

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now